Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

David Cunningham, Seppo Pyrhönen, R.D. James et al. · The Lancet · 1998 · 1.3K citations

Medicine, Oncology, Pharmacotherapy +13

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

C Shih, V J Chen, Lynn S. Gossett et al. · PubMed · 1997 · 565 citations

Medicine, Medicinal Chemistry, Pharmacology +14

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

Cynthia G. Leichman, Thomas R. Fleming, Franco M. Muggia et al. · Journal of Clinical Oncology · 1995 · 361 citations

Medicine, Oncology, Pharmacology +17

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Jessica Conti, Nancy E. Kemeny, Leonard B. Saltz et al. · Journal of Clinical Oncology · 1996 · 343 citations

Medicine, Oncology, Pharmacology +15

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study

Cornelis J.A. Punt, J Burghouts, Jelle J. Croles et al. · Cancer · 1993 · 15 citations

Medicine, Oncology, Pharmacology +15